title: Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
authors: Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany, angenendt@uni-muenster.de.
authors: Linus
authors: L
authors: Angenendt
authors: Andrea
authors: A
authors: Kerkhoff
authors: Stefanie
authors: S
authors: Wiebe
authors: Jan-Henrik
authors: JH
authors: Mikesch
authors: Annika
authors: A
authors: Rudat
authors: Fabian
authors: F
authors: Wötzel
authors: Christian
authors: C
authors: Wenning
authors: Christoph
authors: C
authors: Schliemann
authors: Torsten
authors: T
authors: Kessler
authors: Michael
authors: M
authors: Schäfers
authors: Eva
authors: E
authors: Wardelmann
authors: Matthias
authors: M
authors: Stelljes
authors: Wolfgang E
authors: WE
authors: Berdel
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D005871:Castleman Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D008297:Male; D012074:Remission Induction; D000069283:Rituximab; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation / Q000639:trends*; D014184:Transplantation, Homologous / Q000639:trends
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C502936:tocilizumab